250th Patient screened in EAU Research Foundation's Magnolia Trial
The MAGNOLIA study is a double-blind phase II trial which evaluates the safety and efficacy of antigen-specific cancer immunotherapy with recMAGE-A3 + AS15 in patients with muscle-invasive bladder cancer. This non-commercial study is the first European bladder cancer study sponsored by the EAU Research Foundation, and the only European study evaluating antigen-specific immunotherapy in patients after cystectomy. The study has started in 36 sites in around Europe. New sites from Romania, Ukraine and Russia will be initiated in the next month.